Page last updated: 2024-12-08
licam-c
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
LICAM-C: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 173493 |
MeSH ID | M0107108 |
Synonyms (8)
Synonym |
---|
licam-c |
4-[4-[(4-carboxy-2,3-dihydroxybenzoyl)-[3-[(4-carboxy-2,3-dihydroxybenzoyl)amino]propyl]amino]butylcarbamoyl]-2,3-dihydroxybenzoic acid |
benzoic acid, 4-(((4-((4-carboxy-2,3-dihydroxybenzoyl)amino)butyl)(3-((4-carboxy-2,3-dihydroxybenzoyl)amino)propyl)amino)carbonyl)-2,3-dihydroxy- |
n,n',n''-tris(2,3-dihydroxy-4-carboxybenzoyl)-1,5,10-triazadecane |
75956-68-2 |
DTXSID90226858 |
4-((4-(4-carboxy-2,3-dihydroxybenzamido)butyl)(3-(4-carboxy-2,3-dihydroxybenzamido)propyl)carbamoyl)-2,3-dihydroxybenzoic acid |
AKOS040752563 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" With early treatment and at the dosage used clinically for the decorporation of actinides with DTPA (30 mumol/kg body weight) LICAM(C) was superior to DFOA but when compared with DTPA, the effect of LICAM(C) on 238Pu was greater only in bone; as little as 1 mumol LICAM(C)/kg was as effective as 30 mumol DTPA/kg." | ( Chelation therapy of incorporated plutonium-238 and americium-241: comparison of LICAM(C), DTPA and DFOA in rats, hamsters and mice. Volf, V, 1986) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (18)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 17 (94.44) | 18.7374 |
1990's | 1 (5.56) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |